A recent study examines GLP-1 drugs and mental health, while concerns about long-term effects and access remain. Over 4.9 million patients were represented in 11 primary studies, with nine of 10 cohort studies finding no elevated neuropsychiatric risk.
Psychiatric Safety Confirmed, But Unanswered Questions Remain
A review of 11 primary studies involving over 4.9 million patients found no consistent increase in psychiatric risk associated with GLP-1 receptor agonists (GLP-1RAs), according to a study published in Cureus. The research, which included populations from the U.S., the U.K., Scandinavia, and Poland, examined data for drugs used for T2DM or obesity. The review noted that evidence differed in how mental health was measured and that further research is needed to directly measure mood changes with validated scales.
Reports of suicidal ideation and worsening depressive episodes emerged early in the post-marketing stages of the drugs. However, the U.S. Food and Drug Administration (FDA) subsequently investigated the signal and concluded that available evidence did not support a causal link between GLP-1RAs and suicidal behavior. The presence of GLP-1 receptors in brain regions involved in metabolic and mood regulation has prompted interest in possible neuroprotective or antidepressant effects. Further research is needed to directly measure mood changes with validated scales,
the study authors wrote.
Experts from UT Southwestern, University of Colorado, Cato Institute, and Obesity Action Coalition shared what evidence currently shows about GLP-1 function. They noted that older adults taking GLP-1s who have frailty or a history of heart attack or stroke may need additional clinical support to ensure that they are meeting their nutritional needs and getting sufficient physical activity to mitigate reductions in muscle mass and function. These drugs can produce side effects that may spur changes in eating habits, which can lead to safety risks or worse health outcomes if not appropriately managed,
one panelist noted in a discussion hosted by the National Academy of Medicine.
Cost and Access Challenges
Despite their safety profile, GLP-1 drugs can cost more than $1,000 a month. While insurance coverage and discount programs for individuals can actually reduce the cost by half or more, making these drugs more affordable, they remain out of reach for many Americans. It is often reported that GLP-1 drugs can cost more than $1,000 a month,
noted Tracy Zvenyach of Obesity Action Coalition in a recent analysis. Yet, insurance coverage and discount programs for individuals can actually reduce the cost by half or more, making these drugs more affordable, but still out of reach for many Americans.
Due to the relative expense and scarcity of GLP-1s, online retailers and compounding pharmacies are making alternative formulations available, raising questions about whether these alternative formulas are safe and effective. Since these formulations are regulated differently from name brands, there is often inconsistency in how they are assembled, labeled, and dosed,
a panelist warned during the National Academy of Medicine event. making it challenging for doctors to understand exactly what their patients are taking and how it might affect them.
The debate over access extends beyond affordability. Alex Azar, former Secretary of the US Department of Health and Human Services, highlighted societal stigma surrounding GLP-1 use, comparing it to taking a statin to manage high cholesterol. There is little stigma around taking a statin to manage high cholesterol, but using a GLP-1 to help with weight loss can be perceived by some as “taking the easy way out.”
he said during the discussion. Panelists emphasized that this perception, despite its inaccuracy, persists and may stand in the way of patients accessing these effective treatments or staying on them long-term.
FDA’s Regulatory Shifts
The FDA’s recent warning letter to Novo Nordisk underscores the challenges of monitoring GLP-1 drugs in a rapidly expanding market. The agency found that the manufacturer failed to properly report several serious adverse events linked to GLP-1 medicines, including deaths and a suicide, within the required regulatory timeline for post-marketing safety reporting. The FDA did not conclude the drugs caused those events. The violation was the reporting failure itself. Consolidating the FDA’s adverse event systems and converting to real-time publication was challenging, but made possible by a highly aggressive schedule,
said the Chief AI Officer, Jeremy Walsh in a statement.
The FDA recently launched a unified adverse-event monitoring platform intended to consolidate fragmented safety databases and allow real-time access to reported incidents. The entire safety surveillance system depends on over-reporting first and interpretation later,
one expert noted in a recent analysis. The GLP-1 Safety Picture Is Still Evolving
The Path Forward
As GLP-1 drugs transition from specialist clinics to mass-market prescribing, the center of gravity shifts away from clinical trials and toward post-market surveillance. Researchers emphasize that these medications are effective but operate in a healthcare economy where physicians are not always the primary interface. We need to acknowledge the complexity of the disease [of obesity] and the complexity of well-managed care, and that the relationship between the two is key,
said Tracy Zvenyach during the National Academy of Medicine event.
Policy experts argue that the challenge lies not in whether to use GLP-1s, but how to do so in a more equitable and sustainable way. I think the policy challenge isn’t whether to use GLP-1s, but how to do so in a more equitable and sustainable way.
said Jaime Almandoz of UT Southwestern Medical Center in the same discussion. With the FDA modernizing its surveillance systems and researchers evaluating psychiatric safety and antidepressant potential, the coming years will determine how these therapies are managed.
